Skip to main content
Torrent Pharmaceuticals Ltd. logo

Torrent Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · TORNTPHARM ISIN · INE685A01028 LEI · 335800NA6HK275RIJE13 BSE.NS Manufacturing
Open in API
Filings indexed 1,756 across all filing types
Latest filing 2025-01-15 Call Transcript
Country IN India
Listing BSE.NS TORNTPHARM

About Torrent Pharmaceuticals Ltd.

https://www.torrentpharma.com

Torrent Pharmaceuticals Ltd. is a research-driven organization focused on the development, manufacturing, and marketing of generic formulations. The company holds a significant position in therapeutic areas such as cardiovascular, central nervous system, gastrointestinal, diabetology, and anti-infective treatments. It has strategically expanded its portfolio into dermatology, nephrology, and pain management through targeted acquisitions. The firm operates across multiple international markets, supported by advanced research and development centers and manufacturing facilities that adhere to global regulatory standards. Its core operations prioritize chronic therapy leadership and the provision of high-quality healthcare solutions through a robust pipeline of generic and value-added medicines.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a letter addressed to the stock exchange listing department announcing a post-quarterly financial result conference call scheduled for January 24, 2025, to discuss the financial performance for the quarter ended December 31, 2024. It includes dial-in details and a registration link for the call. The document does not contain any financial data or analysis itself, nor does it present the financial results. It is an announcement of a conference call related to quarterly results, not the transcript or the results release itself. Therefore, it fits the category of a Call Transcript (CT) announcement or invitation. However, since it is only an announcement of the call and not the transcript, and given the classification options, the best fit is Call Transcript (CT) as it relates directly to the conference call content. Confidence is high due to clear references to the conference call and quarterly results discussion.
2025-01-15 English
Post Quarterly Financial Result Conference call with investors / analyst
Call Transcript Classification · 90% confidence The document is a letter addressed to the stock exchange listing department announcing a post-quarterly financial result conference call scheduled for January 24, 2025, to discuss the financial performance for the quarter ended December 31, 2024. It includes dial-in details and a registration link for the call. The document does not contain any financial data or analysis itself, nor does it include a transcript or detailed presentation. It is an announcement of an upcoming event (conference call) related to quarterly results, not the results or transcript themselves. Therefore, it fits best as a Call Transcript (CT) announcement or related to earnings calls. However, since it is only an announcement of the call and not the transcript, and given the classification options, the closest and most appropriate category is Call Transcript (CT) as it pertains to the earnings call event. Confidence is high due to clear mention of the conference call for quarterly results.
2025-01-15 English
Record Date
Notice of Dividend Amount Classification · 95% confidence The document is a formal letter addressed to the National Stock Exchange of India regarding the fixation of a Record Date for the purpose of determining shareholders entitled to an interim dividend. It references Regulation 42 of the SEBI Listing Regulations and specifies the Record Date as 1st February 2025. The content is an announcement related to dividend payment logistics rather than a report or detailed financial data. The document length is short (1730 characters), and it does not contain financial statements or detailed analysis. Therefore, it fits the category of a Notice of Dividend Amount (DIV), as it announces the record date for dividend entitlement, which is a key part of dividend announcements.
2025-01-13 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-01-13 English
Pursuant to Regulation 42 of the Listing Regulations, the Company has fixed Saturday, 01st February, 2025 as the Record Date for taking record of the Members of the Company for the purpose ....
Notice of Dividend Amount Classification · 95% confidence The document is a short notice addressed to the stock exchange regarding the fixing of a Record Date for the purpose of determining shareholders entitled to an interim dividend, if declared. It references Regulation 42 of the SEBI Listing Regulations and specifies the date for the record. There is no financial data, no detailed report, and the document is brief (1742 characters). It is an announcement related to dividend payment timing, not the dividend amount declaration itself. This fits the category of Notice of Dividend Amount (DIV) filings, which include announcements about record dates and dividend payment schedules.
2025-01-13 English
TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2025 ,inter alia, to consider and approve the Audited Financial ....
Regulatory Filings Classification · 95% confidence The document is a letter dated January 13, 2025, addressed to stock exchanges (BSE and NSE) informing them about the date of an upcoming Board Meeting scheduled for January 24, 2025. The letter states that the Board will consider and approve audited and unaudited financial results for the quarter and nine months ended December 31, 2024, and also consider payment of an interim dividend. The document is an intimation or notice about the scheduling of a Board Meeting and the agenda items to be discussed, rather than the actual financial results or reports themselves. It is short (1778 characters) and serves as a notification to the exchanges. According to the classification rules, such a document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not contain the actual financial data or reports. It is not a full financial report, earnings release, or dividend notice, but a notice of a board meeting and agenda.
2025-01-13 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.